An early-phase trial at UNC Lineberger demonstrated that adding the menin inhibitor revumenib to standard azacitidine and venetoclax therapy yields high complete remission rates in AML patients with NPM1 or KMT2A gene alterations. The phase 1 safety study outcomes have prompted a randomized phase 3 trial design to evaluate overall survival benefit. This regimen targets molecularly defined AML subtypes with poor prognoses, representing a personalized therapeutic advance in hematological oncology.